|By Business Wire||
|July 17, 2013 07:01 AM EDT||
Compugen Ltd. (NASDAQ: CGEN) announced today the ongoing development of a Predictive Structural Biology (PSB) Infrastructure Platform designed to computationally identify the functional interaction sites of proteins, which are of substantial importance for the rational design of novel drugs. The current application of this new infrastructure capability aims at enhanced discovery of functional monoclonal antibodies in cancer and immunology, Compugen’s core areas of focus.
Protein interactions are central to key biological functions, and thus the therapeutic applications of modulating such interactions are wide-ranging and of high industry interest. In general, modulation occurs when the drug binds to the protein's functional interaction sites. However, the correct identification of functional interaction sites of proteins has in many cases proven to be challenging. Accurately predicting functional interaction sites would therefore be of great help in the design of novel drugs.
In the area of therapeutic antibodies, which represents one of the fastest growing segments in pharmaceuticals, there have been important advances in multiple technologies developed for accelerating therapeutic antibody discovery. However, generating antibodies having the required biological and therapeutic functions remains very difficult. The current application of the PSB Infrastructure Platform targets this problem.
The development of this new infrastructure platform relies heavily on the integration of capabilities previously developed for Compugen’s PPI Blockers Discovery Platform, such as computational prediction of protein-protein interaction sites, certain protein engineering know-how, and, specifically for the therapeutic antibody application, a molecular analysis of antibody-antigen interactions.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “The flexibility of the PSB Infrastructure Platform creates the potential to provide a wide range of drug discovery capabilities and applications, and therefore it is expected to be an important addition to Compugen’s unique predictive infrastructure.”
Dr. Cohen-Dayag continued, “The current application of this new capability is being designed not only to enhance the discovery of functional therapeutic monoclonal antibodies that modulate Compugen-discovered novel targets, but also to allow us to generate monoclonal antibodies against additional targets, such as those that have to date proven refractory to antibody targeting attempts. The uniqueness of the current application is its focus on functional protein regions, thereby increasing the likelihood of generating functional antibodies with the desired therapeutic activity. Furthermore, future modifications of the current application may enable us to introduce selected specificities to a given antibody in a predictable manner.”
Dr. Cohen-Dayag concluded, “As we further expand our infrastructure for future growth, we continue to be very pleased by the progress we are making in addressing our corporate objectives for 2013. These previously disclosed objectives include entering into collaboration arrangements with respect to certain product candidates in our Pipeline Program, furthering the research and development of product candidates and initiating our second focused area of discovery.”
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. Forward-looking statements in this press release include, but are not limited to, statements relating to the expected ability to, and usefulness of, accurately predicting functional interaction sites of proteins; the potential of providing a wide range of drug discovery capabilities and applications, including enhanced discovery of functional therapeutic antibodies, through the use of the PSB Infrastructure Platform; and the possible future enablement of introducing selected specificities to antibodies in a predictable manner. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Oct. 1, 2016 10:00 AM EDT Reads: 4,658
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Oct. 1, 2016 10:00 AM EDT Reads: 503
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Oct. 1, 2016 10:00 AM EDT Reads: 3,314
What does it look like when you have access to cloud infrastructure and platform under the same roof? Let’s talk about the different layers of Technology as a Service: who cares, what runs where, and how does it all fit together. In his session at 18th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, an IBM company, spoke about the picture being painted by IBM Cloud and how the tools being crafted can help fill the gaps in your IT infrastructure.
Oct. 1, 2016 10:00 AM EDT Reads: 3,194
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Oct. 1, 2016 10:00 AM EDT Reads: 592
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Oct. 1, 2016 09:45 AM EDT Reads: 826
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 1, 2016 09:45 AM EDT Reads: 2,763
In his session at @ThingsExpo, Kausik Sridharabalan, founder and CTO of Pulzze Systems, Inc., will focus on key challenges in building an Internet of Things solution infrastructure. He will shed light on efficient ways of defining interactions within IoT solutions, leading to cost and time reduction. He will also introduce ways to handle data and how one can develop IoT solutions that are lean, flexible and configurable, thus making IoT infrastructure agile and scalable.
Oct. 1, 2016 09:15 AM EDT Reads: 1,672
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
Oct. 1, 2016 09:00 AM EDT Reads: 2,940
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Oct. 1, 2016 08:45 AM EDT Reads: 5,504
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
Oct. 1, 2016 08:30 AM EDT Reads: 2,507
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Oct. 1, 2016 08:30 AM EDT Reads: 3,416
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
Oct. 1, 2016 08:00 AM EDT Reads: 1,313
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, will discuss recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model f...
Oct. 1, 2016 08:00 AM EDT Reads: 2,274